Showing 1 - 5 results of 5 for search 'K. Manousou', query time: 0.02s Refine Results
  1. 1
    Experimental Implementation and Theoretical Investigation of a Vanadium Dioxide Optical Filter for Bit Error Rate Enhancement of Enhanced Space Shift Keying Visible Light Communication Systems

    Experimental Implementation and Theoretical Investigation of a Vanadium Dioxide Optical Filter for Bit Error Rate Enhancement of Enhanced Space Shift Keying Visible Light Communica... by Dimitra K. Manousou, Argyris N. Stassinakis, Emmanuel Syskakis, Hector E. Nistazakis, Spiros Gardelis, George S. Tombras

    Published 2019-06-01
    Get full text
    Article
  2. 2
    S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY

    S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCI... by E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, D. Fotiou, N. Kanellias, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.-A. Dimopoulos

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

    P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK by E. Kastritis, M. C. Minnema, M. A. Dimopoulos, G. Merlini, F. Theodorakakou, D. Fotiou, A. Huart, K. Belhadj, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, G. Palladini

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

    P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK by E. Kastritis, G. Palladini, M. A. Dimopoulos, A. Jaccard, G. Merlini, F. Theodorakakou, D. Fotiou, M. C. Minnema, A. Wechalekar, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, S. Schönland

    Published 2022-06-01
    Get full text
    Article
  5. 5
    P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

    P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL by I. Ntanasis-Stathopoulos, M. Gavriatopoulou, P. Malandrakis, D. Fotiou, N. Kanellias, M. Migkou, F. Theodorakakou, V. Spiliopoulou, R. Syrigou, E. Eleutherakis-Papaiakovou, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.A. Dimopoulos, E. Terpos

    Published 2023-05-01
    Get full text
    Article

Search Tools: